Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Personalized Medicine Opportunity Analysis - Team Neuropeptide - Stanford VentureLab 2012


Published on

Opportunity analysis project report by Team Neuropeptide, Stanford VentureLab class 2012. Our team is exploring business opportunities in the area of overlap of the fields of neurocomputation, genomics, and medicine. We are looking for successful ways to use neuromorphic algorithms for mining genomic databases and create opportunities for modern agile business models in more accessible and personalized healthcare.

Published in: Health & Medicine, Business
  • Be the first to comment

  • Be the first to like this

Personalized Medicine Opportunity Analysis - Team Neuropeptide - Stanford VentureLab 2012

  1. 1. Personalized Medicine The technologies are here  Are you ready to invest and help patients?Opportunity Analysis Project for the Stanford Technology Ventures Course 2012 Submitted by Team Neuropeptide
  2. 2. What is personalized medicine?Personalized medicine is generally understood as the use of molecularanalysis to achieve optimal medical outcomes in the management ofpatient’s disease or disease predisposition(Based on the definition from the Personalized Medicine Coalition)Our primary business objectives: i) Development of a comprehensive machine learning framework to identify molecular signatures in patients with the highest unmet medical needs i.e. oncology/cancer ii) Development of personalized medical treatments that might include targeted personalized drugs tailored to individual genetics
  3. 3. Patients with unmet medical needs want more effective treatments with fewer side effects● Over 50% of prescribed drugs are not efficacious. The option for healthcare providers and patients was an expensive and inefficient trial and error approach based on arcane technologies. Our society can not afford the status quo anymore● Patients as well as healthy people desire personalized medical care Personalized Medicine Attitude Survey Results, VL Neuropeptide Team, 2012
  4. 4. Changes are coming...• The paradigm shift in health care is here to stay andvisionary informatics and biotech entrepreneurs have beenpositioning themselves to gain early entry advantage inthis new era• FDA getting proactive to prevent adverse drug effects• FDA getting proactive at supporting personalizedmedicine technologies and research initiativesBiomarkers, SNPs, NGS, Microarrays, Genomics, Proteomics, Imaging,Diagnostics and Targeted Personalized Therapeutics
  5. 5. A Mandate: The right drug to the right patient at the right time (Leroy Hood)• Multiple approaches to develop the best treatment for the individualpatient• Capitalize on current advances in computational biology to speed upthe discovery of personalized biologics• Started with diagnostics moving fast into personalized therapeuticsSome Venture Capital firms shifted their investments overseas whereregulatory approvals come quicker;The U.S. Food and Drug Administration is taking steps to addresssome of the industrys concerns; the agency plans to streamlineregulations and speed up the approval process for some, Oct 6, 2011
  6. 6. How should medicine be reformed?● The progress of clinical trials should be made readily available● Patient privacy should be observed if requested by the patient, but depersonalized genomic and clinical data should be freely shared and exchanged● The power of outside interests (big pharma, insurance, etc.) should be explicitly curtailed. An industry-wide black list for cases of collusion, probable bias, and misleading results should be kept with free access● The field should embrace computation and big data to accelerate research and create a framework for personalized medicine● Better integration of computers in clinical practice and better utilization of data produced● Better MR scanners and better BCIs
  7. 7. What are the biggest roadblocks in medicine today?● Perceived unbalanced use of personal information by healthcare and insurance entities may be generating mistrust and a feeling of helplessness in people● Low quality of body of research caused by an enormous amount of biased and unverified experimental findings usually due to outside interests or ulterior motives● Slow introduction of computational power into the medical field in general● The idea that complex psychological phenomena can be explained by quite simple biological factors (alone)● Hierarchical and traditional structure● Lack of emancipated patient participation
  8. 8. What are the advantages of personalization?What are the advantages of personalization? Arcane Reactive Medical Care Efficient Medical Care Not just personalized drug selection but personalized drug development!Costly and inefficient trial and Improved Quality Careerror approach Adapted fromfrom Personalized Medicine Coalition report, Adapted public public Personalized Medicine Coalition report
  9. 9. The goal of the Personalized Medicine CoalitionFigure taken from the PMC website
  10. 10. Genotype Analysis Attitude Data from our surveyHow likely are you to get your genotypeconfidentially analyzed for you (possible for $300)? Personalized Medicine Attitude Survey Results, VL Neuropeptide Team, 2012
  11. 11. Personalized drug consumer attitude data from our surveyHow likely are you to get yourwhole genome sequenced and n=55analyzed for the development ofyour own personalizedexperimental drug(s)?Conclusion:Our sample size is not large enough(n=55) to draw a statistically relevantconclusion with respect to the degree ofwillingness to have own genomesequenced and analyzed fordevelopment of own drugs.However, it is apparent from theresponses that people that are not likelyto do it are a minority with respect tothose that could eventually do it. Wepredict that with proper education on thesubject, ~75% of the people will be verylikely to do it. Personalized Medicine Attitude Survey Results, VL Neuropeptide Team, 2012
  12. 12. Personalized health care consumer attitude data from our surveyWhen do you think it will bepossible to provide personalizedhealth care? n=55Conclusion:From a sample size n=55, weobserve an overall optimisticpublic attitude toward the abilityto realize and implement fullpersonalized health care in thecoming years.We hypothesize that with bettereducation about the subject, thegeneral perception of the publicwill tend to be skewed towardshorter development andimplementation times Personalized Medicine Attitude Survey Results, VL Neuropeptide Team, 2012
  13. 13. Market Projections in Personalized Medicine● Projected to grow 11.56% annually● Estimated U$ 232MM● Expected to double by 2015 to over 450MM● Mostly from Genomics and Proteomics
  14. 14. Bay area proactive